Want to see IN:BALAXI full AI Analyst Report?
BALAXI Stock Chart & Stats
₹27.06
-₹2.28(-2.93%)
At close: 4:00 PM EST
₹27.06
-₹2.28(-2.93%)
Day’s Range― - ―
52-Week Range₹15.20 - ₹52.50
Previous CloseN/A
Volume27.88K
Average Volume (3M)75.37K
Market Cap
₹1.31B
Enterprise Value₹696.20M
Total Cash (Recent Filing)₹145.59M
Total Debt (Recent Filing)₹576.49M
Price to Earnings (P/E)92.3
Beta1.17
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.26
Shares Outstanding55,207,500
10 Day Avg. Volume158,740
30 Day Avg. Volume75,367
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)0.34
Price to Sales (P/S)0.31
P/FCF Ratio-1.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Moderate Leverage And Sizable Equity BaseLow debt-to-equity (~0.23) and a sizable equity base provide structural financial flexibility. Over a multi-month horizon this reduces refinancing and solvency risk, enabling the firm to fund working capital or strategic initiatives without immediate distress despite episodic cash-flow weakness.
Solid Gross Margin Foundation (~41.7%)A gross margin near 42% signals durable product-level profitability and a buffer to absorb SG&A or distribution costs. This structural margin supports potential margin recovery if operating expenses are controlled and provides competitive pricing flexibility across domestic and export markets.
Diversified Revenue Model: Domestic Sales And ExportsA business model split between domestic distribution and exports creates durable revenue diversification and lowers single-market dependency. Long-term, a distribution/export mix can stabilize demand cycles, enable scale benefits, and leverage existing marketing networks for product expansion.
Bears Say
Recurring Negative Operating And Free Cash FlowSustained negative operating and free cash flow materially raises funding risk. Over 2–6 months this limits the firm's ability to fund inventories, exports, or capex internally, increases reliance on external financing, and constrains investment in growth or margin-improving initiatives.
Severe Deterioration In Profitability And ROEA collapse in net margin and ROE signals weak earnings quality and poor returns on invested capital. Structurally this undermines the company's ability to self-finance growth, reduces investor confidence, and suggests persistent cost or pricing pressures that could be hard to reverse quickly.
Choppy Top-line: Recent Revenue Slip And VolatilityErratic revenue trends and a slip below prior-year levels point to unstable demand or competitive pressure. Over the medium term this raises concerns about sustaining scale economies, forecasting, and margin recovery, making long-term planning and investment returns more uncertain.
Balaxi Pharmaceuticals Limited News
BALAXI FAQ
What was Balaxi Pharmaceuticals Limited’s price range in the past 12 months?
Balaxi Pharmaceuticals Limited lowest stock price was ₹15.20 and its highest was ₹52.50 in the past 12 months.
What is Balaxi Pharmaceuticals Limited’s market cap?
Balaxi Pharmaceuticals Limited’s market cap is ₹1.31B.
When is Balaxi Pharmaceuticals Limited’s upcoming earnings report date?
Balaxi Pharmaceuticals Limited’s upcoming earnings report date is Jul 30, 2026 which is in 23 days.
How were Balaxi Pharmaceuticals Limited’s earnings last quarter?
Balaxi Pharmaceuticals Limited released its earnings results on May 28, 2026. The company reported ₹0.11 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.11.
Is Balaxi Pharmaceuticals Limited overvalued?
According to Wall Street analysts Balaxi Pharmaceuticals Limited’s price is currently Overvalued.
Does Balaxi Pharmaceuticals Limited pay dividends?
Balaxi Pharmaceuticals Limited pays a Notavailable dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Balaxi Pharmaceuticals Limited dividends here
What is Balaxi Pharmaceuticals Limited’s EPS estimate?
Balaxi Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Balaxi Pharmaceuticals Limited have?
Balaxi Pharmaceuticals Limited has 55,207,500 shares outstanding.
What happened to Balaxi Pharmaceuticals Limited’s price movement after its last earnings report?
Balaxi Pharmaceuticals Limited reported an EPS of ₹0.11 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Balaxi Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:BALAXI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Balaxi Pharmaceuticals Limited
Balaxi Pharmaceuticals Limited, through its entity Balaxi Ventures Ltd., primarily operates as an international wholesale distributor specializing in pharmaceuticals, various food items, and hardware supplies. The company's corporate base is situated in Hyderabad, Telangana. Its extensive product range features pharmaceutical formulations, a variety of food products, and construction-related hardware. Notably, both its pharmaceutical and builders' hardware offerings are manufactured under contract at different plants located across India. Within its food segment, the firm markets a selection of food and biscuit products under the recognizable brand name YAP. Balaxi Global DMCC is among the key subsidiaries within the company's structure.
Technical Analysis
Biofil Chemicals & Pharmaceuticals Ltd.
―
Gkb Ophthalmics Limited
―
―
Lasa Supergenerics Ltd.
―
Vivimed Labs Limited
―